跳至主要内容
临床试验/CTRI/2019/01/017317
CTRI/2019/01/017317已完成3 期

Efficacy and safety of olanzapine as an add on therapy in children receiving highly emetogenic chemotherapy: A Randomized Double Blind Placebo Controlled Trial

All India Institute of Medical Sciences0 个研究点目标入组 128 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
入组人数
128

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Planned for single day highly emetogenic chemotherapy (as defined by Pediatric Oncology Group of Ontario guidelines)
  • 2) Absolute neutrophil count > 1000/mm3, Platelet count > 1 lakhs
  • 3) SGOT/SGPT < 3 times upper limit of normal and serum bilirubin < 1.5 times upper limit of normal
  • 4) Written informed consent

排除标准

  • 1) Hypersensitivity to olanzapine
  • 2) Patients with primary/ metastatic brain tumor
  • 3) Received olanzapine within 3 weeks or another antipsychotic 30 days prior to enrolment
  • 4) CYP1A2 inducers or inhibitors while receiving olanzapine
  • 5) Vomiting within 24 hour prior to treatment
  • 6) Steroids within 24 hour prior to enrolment

研究者

相似试验